Sandostatin LAR in acromegalic patients: a dose-range study.

@article{Flgstad1995SandostatinLI,
  title={Sandostatin LAR in acromegalic patients: a dose-range study.},
  author={A K Fl\ogstad and Johan I. Halse and Torbj\orn Haldorsen and Ioana Lancranjan and Peter Marbach and Christian J. Bruns and Jak Jervell},
  journal={The Journal of clinical endocrinology and metabolism},
  year={1995},
  volume={80 12},
  pages={3601-7}
}
Sandostatin LAR is a sustained release formulation of octreotide that has been developed by microencapsulating the drug with biodegradable poly(lactide-glycolide)-glucose. We have investigated the efficacy and tolerability of Sandostatin LAR given as a single dose im to patients with active acromegaly who showed good GH suppression during a 2- to 4-week pretreatment period with octreotide given sc. Two double blind studies were performed. Initially, 14 patients were randomized and observed over… CONTINUE READING

Similar Papers

Loading similar papers…